Navigation Links
YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
Date:9/4/2007

Data Presented at the 12th World Conference on Lung Cancer in Seoul, Korea

MISSISSAUGA, ON, Sept. 4 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced positive preliminary results from the first two cohorts of the Phase I part of a Phase I/II trial of nimotuzumab in combination with radiation for the treatment of non-small-cell lung cancer (NSCLC) patients who are unsuitable for radical chemotherapy. The data were reported on September 5th in a poster presentation at the 12th World Conference on Lung Cancer in Seoul, Korea. Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR).

"While preliminary, these results are compelling because we observed clinical benefit (Partial Response or Stable Disease) in every one of the 13 patients so far enrolled in this study. A study by The National Cancer Institute of Canada demonstrated that patients with advanced NSCLC with Stable Disease as best response for treatment had Overall Survival similar to patients with Partial Response. The relatively long survival times observed in the first cohort of this trial are encouraging and are in agreement with the NCIC observations," said Dr. Igor Sherman, YM's Director of Clinical Research. "Although nimotuzumab specifically targets the EGF receptor, the reported absence of side effects, particularly the absence of severe rash, makes nimotuzumab therapeutically attractive in this setting."

The Phase I component enrolled patients at three centers in Canada and is evaluating the safety and feasibility of administrating nimotu
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 With bed bugs' presence ... that although bed bugs need to be eliminated, one must ... compromise a person's health. And so to help bed bug ... get rid of bed bugs without using harmful ... bug spray it called Bed Bug Bully. , According to ...
(Date:5/20/2013)... PA (PRWEB) May 20, 2013 Interventional ... Allegheny General Hospital (AGH) Cardiovascular Institute have ... coronary artery disease (CAD) over the past ... such as balloon angioplasty and coronary artery stent implantation. ... once again play a prominent role in the study ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 In Early ... the field of biotoxin related illnesses , announced his ... country able to advance his protocol for treating Chronic ... became the third physician to achieve certification in the ... Physicians, able to practice the Shoemaker Protocol in other ...
(Date:5/17/2013)... GA (PRWEB) May 17, 2013 Dr. ... Gynecology, and Women’s Health at the Albert Einstein College ... Oncology at the Montefiore Medical Center. He is ... Cancer Center and leads the Einstein Breast Cancer Working ... on translational breast cancer research. He also serves as ...
Breaking Biology Technology:New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3
... BOTHELL, WA and VANCOUVER, May 11 /PRNewswire-FirstCall/ - ... announced today that final survival data from a ... with docetaxel versus docetaxel alone as first-line chemotherapy ... be featured in an oral presentation at the ...
... manufacturer, Sepha Ltd, enters strategic European alliances and gears up for ... , ... Belfast (Vocus) May 11, 2009 -- The ... de-blistering equipment, Sepha Ltd is boosting its European distribution ...
... attempt to dismiss Bavarian Nordic,s patent infringement suit in ... Biomedica,made yet another attempt to dismiss the suit arguing ... clinical trials. The court ruled,against Oxford Biomedica and the ... patents. , Bavarian Nordic owns ...
Cached Biology Technology:OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting 2OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting 3Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution 2Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution 3The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica 2
(Date:5/17/2013)... State University of New Jersey, and City University of ... Visikol TM that effectively clears organisms to be ... of chloral hydrate, which is one of the few ... regulated by the Drug Enforcement Administration (DEA) due to ... clearing agents, are vital for viewing organisms under a ...
(Date:5/17/2013)... proteins in the brain responsible for protecting nerve cells ... increase cell survival. , The discovery, made by researchers ... the EMBO journal with additional comment in ... stroke and other brain diseases. , The research builds ... protein, known as SUMO, responsible for controlling the chemical ...
(Date:5/17/2013)... project (Intelligent Cargo in Efficient and Sustainable Global Logistics ... an improvement in the efficiency of intermodal loading systems ... making. It comprises 29 European organisations with experience in ... has a budget totalling 17,000,000 and a duration of ... to specify and develop the semantic components and ontologies ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3SUMO wrestling cells reveal new protective mechanism target for stroke 2New logistics services that will cut energy consumption and CO2 emissions 2
... Leading bioscience funding bodies in the UK and USA ... transformational area of enhanced photosynthesis. The Biotechnology and ... Science Foundation (NSF) announce plans to hold an intensive ... in California later this year, to bring together leading ...
... of Cedars-Sinai Medical Center in Los Angeles, was presented ... annual Lifetime Achievement Award at its 2010 Annual Meeting. ... of contributions to genetic medicine, for his research into ... for helping to organize the field of medical genetics ...
... new tool to help marine biologists better grasp the processes ... unveil the bacterial community dynamics behind afflictions that bleach and ... March 30, 2010.) Warming waters are triggering coral ... Barrier Reef off the Australian coast. Now new mathematical models ...
Cached Biology News:BBSRC and NSF join together to promote new ideas to enhance photosynthesis 2Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 2Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 3New mathematical model helps biologists understand how coral dies in warming waters 2
... This adapter allows ... (AB-0800 and AB-1000) PCR ... in the ABI PRISM® ... contact ABgene® for information ...
... Heat activated ,• Eliminates nonspecific ... ,• Excellent specificity allows extension through ... structures ,• Leaves an 'A' overhang ... form of GeneChoice DNA Polymerase that ...
... aqueous solution. Cleaves a-(1-3)- ... carbohydrates and glycoproteins. It is particularly efficient ... the pH must be neutral or above, ... Unit Definition: One unit will ...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
Biology Products: